ValuEngine upgraded shares of Lannett Co Inc (NYSE:LCI) from a hold rating to a buy rating in a report issued on Monday morning.

LCI has been the subject of a number of other reports. Deutsche Bank AG reiterated a hold rating and set a $23.00 target price (up from $22.00) on shares of Lannett Co in a research report on Monday, July 17th. Roth Capital set a $27.00 target price on Lannett Co and gave the company a buy rating in a research report on Tuesday, August 22nd. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Lannett Co in a research report on Thursday, June 8th. BidaskClub downgraded Lannett Co from a buy rating to a hold rating in a research report on Monday, July 24th. Finally, Zacks Investment Research upgraded Lannett Co from a hold rating to a buy rating and set a $25.00 target price for the company in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $21.80.

Lannett Co (NYSE LCI) traded up 0.124% on Monday, hitting $20.225. 151,787 shares of the company’s stock traded hands. The stock’s market cap is $754.07 million. Lannett Co has a 12 month low of $14.90 and a 12 month high of $28.08. The stock has a 50 day moving average price of $17.39 and a 200-day moving average price of $20.19.

Lannett Co (NYSE:LCI) last posted its earnings results on Wednesday, August 23rd. The company reported $0.40 EPS for the quarter, meeting analysts’ consensus estimates of $0.40. The firm had revenue of $139.10 million during the quarter, compared to the consensus estimate of $139.01 million. Lannett Co had a positive return on equity of 19.80% and a negative net margin of 0.09%. The company’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.73 EPS. Equities analysts predict that Lannett Co will post $2.57 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/lannett-co-inc-lci-upgraded-at-valuengine.html.

A number of large investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System raised its holdings in Lannett Co by 0.7% during the 2nd quarter. Arizona State Retirement System now owns 15,362 shares of the company’s stock valued at $313,000 after buying an additional 100 shares during the period. CS Mckee LP raised its holdings in Lannett Co by 0.6% during the 2nd quarter. CS Mckee LP now owns 35,400 shares of the company’s stock valued at $722,000 after buying an additional 200 shares during the period. Texas Permanent School Fund raised its holdings in Lannett Co by 1.0% during the 2nd quarter. Texas Permanent School Fund now owns 21,474 shares of the company’s stock valued at $438,000 after buying an additional 203 shares during the period. Rhumbline Advisers raised its holdings in Lannett Co by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 61,600 shares of the company’s stock valued at $1,257,000 after buying an additional 244 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Lannett Co by 1.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,366 shares of the company’s stock valued at $456,000 after buying an additional 297 shares during the period. Institutional investors own 87.92% of the company’s stock.

About Lannett Co

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Lannett Co (NYSE:LCI)

Receive News & Stock Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related stocks with our FREE daily email newsletter.